Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs continued corticosteroids in idiopathic nephrotic syndrome unresponsive to high-dose prednisone
2017-003366-27Phase 3Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Complete remission rate. Started Oct 2017; status: terminated.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2017-003366-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003366-27.